Roche is gearing up to launch an eye implant that promises to make its Lucentis macular degeneration treatment easier to use. But the Swiss drugmaker isn't stopping there with the tiny device. It's aiming for new indications for Lucentis therapy—and new pairings with next-gen antibodies, too.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,